In a rare feat in the nation's drug approval history, the Central Drugs Standard Control Organisation (CDSCO) has provided approval to three Covid-19 related drugs in a single day. The drug regulator had approved Corbevax vaccine, Covovax vaccine and anti-viral drug molnupiravir on Tuesday, for restricted use in emergency situation, said Union minister for health and family welfare Dr Mansukh Mandaviya. The measure is to further strengthening the fight against Covid-19, he said. Corbevax vaccine, from Hyderabad-based Biological E is India's first indigenously developed RBD protein sub-unit vaccine against Covid-19. This is the third vaccine developed in India, he added. The nanoparticle vaccine, Covovax, developed by US based Novavax and will be manufactured by Pune-based firm Serum Institute of India. "Molnupiravir, an antiviral drug, will now be manufactured in the country by 13 companies for restricted use under emergency situation for treatment of adult patients with Covid-19 and who have high risk of progression of the disease," added the Minister. "Our pharma Industries are asset for the entire world," he averred. It may be noted that the Prime Minister Narendra Modi, in his address to the nation earlier this week has announced India's plans to administer vaccine to children and provide booster dose to the elderly and frontline staff.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!